Compare Neurocrine Biosciences Inc (NBIX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Upwork Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Upwork Inc trades at $8.31 (market cap $1.04B). The key difference: Neurocrine Biosciences Inc is far larger — about 15.2× Upwork Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | UPWK | |
|---|---|---|
Market Cap | $15.77B | $1.04B |
Sector | Health | Industrials |
52-Week High | $185.50 | $22.11 |
52-Week Low | $123.10 | $7.84 |
Enterprise Value | $15.78B | $802.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Upwork (UPWK) is trading at $8.32, down 5.35% on the day, with a bearish technical signal and recent earnings volatility. The company maintains strong profitability metrics including a 77.21% gross margin and 12.93% net income margin, though Q2 2026 earnings beat was overshadowed by weak guidance. Recent news highlights multiple securities fraud investigations alongside AI integration developments.
The stock presents a mixed outlook with attractive valuation multiples (P/E 10.67, P/S 1.44) but faces headwinds from AI disruption and legal scrutiny. Analyst consensus leans bullish with a $9.00 price target, though technical indicators suggest near-term pressure with support at $8.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
